Fibroblast heterogeneity in the diseased lung

K. Heinzelmann, G. Preissler, H. Winter, R. Hatz, I. Koch, M. Lindner, J. Behr, O. Eickelberg (Munich, Gauting, Germany)

Source: International Congress 2014 – ILDs 3
Session: ILDs 3
Session type: Thematic Poster Session
Number: 788
Disease area: Interstitial lung diseases

Congress or journal article abstract

Abstract

Chronic lung diseases (CLD), such as chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF), are characterized by altered cellular composition and activation, as well as extracellular matrix (ECM) remodeling. Fibroblasts are thought to be the main ECM producing cell type in the lung. In this study, we hypothesized that different mesenchymal subpopulations within the human lung exhibit different surface marker profiles, and which might respond differentially to TGFbeta - a central key player in IPF and COPD.Primary human fibroblasts were isolated from human lung parenchyma (n=5), taken in culture and treated with TGFbeta or left untreated for 48 hours. Western Blot (WB) and FACS analysis was performed to determine changes on the protein level and in the percentage of cells for ECM components and surface markers such as fibronectin, type I collagen, desmin, PDGFRa, CD90/Thy-1 and HMMR.In FACS analysis 97% (±1.5) of fibroblasts were CD90/Thy-1 positive, whereas 57% (±12.8) were positive for fibronectin, 65% (±12.2) for type I collagen, 48% (±4.2) for desmin, 16% (±15.5) for PDGFRa and 7% (±5.8) for HMMR. After stimulating with TGFbeta, no changes on the protein level or in the percentage of cells could be detected for desmin (44% ±13.0) and CD90 (96% ±3.0), whereas a decrease could be observed for PDGFRa (0% ±0) as well as for HMMR (1% ±0.9), and an increase for fibronectin (80% ±8.0) and type I collagen (83% ±5.4). Similar results could be detected by WB.In sum, we document that different subpopulations exist within the human lung, and which respond differentially to the growth factor TGFbeta in their marker expression. This indicates that different fibroblast subtypes play distinct roles in COPD or IPF.


Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. Heinzelmann, G. Preissler, H. Winter, R. Hatz, I. Koch, M. Lindner, J. Behr, O. Eickelberg (Munich, Gauting, Germany). Fibroblast heterogeneity in the diseased lung. Eur Respir J 2014; 44: Suppl. 58, 788

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The role of CCR2+CD4+T cells in lung fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014

Mucus production, lung inflammation and functional decay in IPF
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014

Parenchymal cell populations involved in the development of fibrosis
Source: International Congress 2014 – ILDs 4
Year: 2014

Neuroendocrine cell hyperplasia (NEHI) and NEHI Syndrome: Lung biopsy necessary?
Source: International Congress 2014 – ILDs 4
Year: 2014


Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014

Pregnancy course in patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014


Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases
Source: International Congress 2014 – ILDs 4
Year: 2014


Interstitial lung disease in the connective tisssue disease
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014


Aetiological panorama in the diagnosis of interstitial lung diseases
Source: International Congress 2014 – ILDs 5
Year: 2014


Beneficial effect of azithromycin in children with diffuse parenchymal lung disease
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Evolution of an interstitial lung disease MDT: 5.5 years of data
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias
Source: International Congress 2014 – IPF and surroundings
Year: 2014



Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 6
Year: 2014

Lung 18F-FDG uptake correlates with lung function alteration in patients with IPF
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014


Type V collagen induced pulmonary fibrosis in C57Bl/6mice
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014

Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 2
Year: 2014

Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014

Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement
Source: International Congress 2014 – ILDs: connective tissue disease
Year: 2014


Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease?
Source: International Congress 2014 – ILDs 5
Year: 2014

Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis
Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations
Year: 2014